Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Brazikumab (DHJ63104)

Host species:Human
Isotype:IgG2-lambda
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHJ63104

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Human

Isotype

IgG2-lambda

Clonality

Monoclonal

Target

SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NPF7

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

AMG-139, MEDI2070, CAS: 1610353-18-8

Clone ID

Brazikumab

Data Image
  • SDS-PAGE
    SDS PAGE for Brazikumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease, PMID: 29991933

Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease, PMID: 30571147

Anti-interleukin-23 agents for the treatment of ulcerative colitis, PMID: 31760827

Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More, PMID: 32570252

Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease, PMID: 30884245

IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?, PMID: 31327402

Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease, PMID: 30056776

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis, PMID: 31447673

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?, PMID: 28765121

The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges, PMID: 34079536

Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease, PMID: 28838418

Datasheet

Document Download

Research Grade Brazikumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Brazikumab [DHJ63104]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only